* [CHEETAH](http://doi.org/10.1056/NEJMoa1616325) (2017)
	* 506 adults undergoing cardiac surgery with severe cardiovascular dysfunction (LVEF <25%, pre-operative IABP, intraoperative IABP required)
	* Multicentre (14) parallel-group trial across Italy, Russia, and Brazil
	* 1000 patients provides 80% power for 5% ↓ in absolute mortality
	* Levosimendan at 0.05-0.2μg/kg/min for up to 48 hours vs. placebo
	* Terminated early for futility
	* No difference in mortality